Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.4K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.4K
Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Drug Nomenclature01:17

Drug Nomenclature

1.6K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.6K
Pharmacovigilance01:19

Pharmacovigilance

769
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
769
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Characterizing the MSMP-CCR2 Interaction through Molecular Dynamics Simulations and Machine Learning Approaches.

Journal of chemical information and modeling·2026
Same author

Exploring the association between common genetic deletions and aging: insights from the Canadian Longitudinal Study on Aging.

GeroScience·2026
Same author

META-DIFF: a k-mer-based pipeline that detects differentially abundant sequences in metagenomics whole genome sequencing.

Scientific reports·2026
Same author

Editorial: Advances in systems biology and bioinformatics for microbiology research.

Canadian journal of microbiology·2026
Same author

An intricate functional relationship between NuA4 and Sfp1 regulates ribosome biogenesis in response to nutrient availability.

The Journal of biological chemistry·2026
Same author

MIZ-1 controls transcriptional programs required for BCR signaling, actin dynamics, and naïve B cell survival.

Frontiers in immunology·2026

相关实验视频

Updated: May 29, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

478

使用大型语言模型,通过负数据标签改进药物重新定位.

Milan Picard1, Mickael Leclercq1, Antoine Bodein1

  • 1Molecular Medicine Department, CHU de Québec Research Center, Université Laval, Québec, QC, Canada.

Journal of cheminformatics
|February 5, 2025
PubMed
概括
此摘要是机器生成的。

这项研究引入了一种使用大型语言模型 (LLM) 识别真正负面药物的新方法,显著提高了前列腺癌药物重新定位的准确性,并确定了980个潜在的候选人.

关键词:
人工智能驱动的药物发现生物医学文本挖掘技术割抵抗性前列腺癌是什么?计算药物评分计算药物评分药物重新定位是药物重新定位.负数据标签 负数据标签

更多相关视频

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.4K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

相关实验视频

Last Updated: May 29, 2025

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness
03:14

Augmenting Large Language Models via Vector Embeddings to Improve Domain-Specific Responsiveness

Published on: December 6, 2024

478
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.4K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.1K

科学领域:

  • 计算生物学是一种计算生物学.
  • 药物发现 药物发现
  • 机器学习 机器学习

背景情况:

  • 药物重新定位可以加速开发并降低成本,但受到负面数据稀缺的限制 (由于无效或毒性而失败的药物).
  • 现有的积极未标记 (PU) 学习方法因难以获得可靠的负面药物数据而难以错误分类和简化决策边界.

研究的目的:

  • 利用大型语言模型 (LLM) 开发一种新的策略,系统地识别真正的负面药物.
  • 提高药物重新定位的监督机器学习模型的准确性和概括性.
  • 为了确定前列腺癌治疗的潜在候选药物.

主要方法:

  • 利用大型语言模型 (GPT-4) 来分析前列腺癌的临床试验,并识别真正的负药物.
  • 创建了一个由26种阳性药物和54种验证的阴性药物组成的培训数据集.
  • 应用了机器学习组合来选来自DrugBank数据库的11,043种药物,以寻找潜在的重新用途.

主要成果:

  • 与传统的PU学习方法 (0.55和0.48) 相比,基于LLM的策略显著提高了预测准确性 (马修斯相关系数为0.76).
  • 从11,043种选的药物中确定了980种潜在的前列腺癌候选药物.
  • 对前30名候选药物的详细审查揭示了9种有希望的药物,这些药物针对基因组不稳定性和p53调节等关键机制.

结论:

  • 使用LLM开发的负数据标签方法可以大幅提升监督药物重新定位.
  • 将这种方法扩展到ClinicalTrials.gov中的所有疾病中,为发现新疗法提供了更准确,数据驱动的方法.
  • 该战略承诺通过克服传统药物开发管道的局限性,加快有效治疗方法的识别.